Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1

Genes Chromosomes and Cancer

Volumn 56, Issue 2, 2017, Pages 147-158

  Damiano, Valentina ^a   Brisotto, Giulia ^a   Borgna, Silvia ^a   di Gennaro, Alessandra ^a   Armellin, Michela ^a   Perin, Tiziana ^a   Guardascione, Michela ^a   Maestro, Roberta ^a   Santarosa, Manuela ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; MICRORNA 141; MICRORNA 200C; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; MESSENGER RNA; MICRORNA; MIRN200 MICRORNA, HUMAN; TUMOR MARKER; ZEB1 PROTEIN, HUMAN;

ADULT; AGGRESSIVENESS; ARTICLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE LOCUS; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; APOPTOSIS; CANCER GRADING; CANCER STAGING; CELL MOTION; CELL PROLIFERATION; ENZYME IMMUNOASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING;

APOPTOSIS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DNA METHYLATION; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 85003666407     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22422     Document Type: Article

References (47)

1. Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn C-O, Heidecke C-D, Friess H, Büchler M, Evert M, Lerch MM, Weiss FU. 2012. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61:439–448.
2. Ambrosio R, Damiano V, Sibilio A, De Stefano MA, Avvedimento VE, Salvatore D, Dentice M. 2013. Epigenetic control of type 2 and 3 deiodinases in myogenesis: Role of Lysine-specific Demethylase enzyme and FoxO3. Nucleic Acids Res 41:3551–3562.
3. Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-Wittmann S, Caron de Fromentel C, Puisieux A. 2008. Induction of EMT by Twist Proteins as a Collateral Effect of Tumor-Promoting Inactivation of Premature Senescence. Cancer Cell 14:79–89.
4. Berx G, van Roy F. 2009. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harbor Perspectives in Biology 1:a003129.
5. Borgna S, Armellin M, di Gennaro A, Maestro R, Santarosa M. 2012. Mesenchymal traits are selected along with stem features in breast cancer cells grown as mammospheres. Cell Cycle 11:4242–4251.
6. Brisotto G, di Gennaro A, Damiano V, Armellin M, Perin T, Maestro R, Santarosa M. 2015. An improved sequencing-based strategy to estimate locus-specific DNA methylation. BMC Cancer 15:639.
7. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. 2008. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9:582–589.
8. Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y. 2012. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 31:4619–4629.
9. Castilla MA, Díaz-Martín J, Sarrio D, Romero-Perez L, Lopez-Garcia MA, Vieites B, Biscuola M, Ramiro-Fuentes S, Isacke CM, Palacios J. 2012. MicroRNA-200 Family Modulation in Distinct Breast Cancer Phenotypes. PLoS ONE 7:e47709.
10. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, Allgayer H. 2010. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8:1207–1216.
11. Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F, Esteller M. 2012. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 31:2062–2074.
12. Díaz-Martín J, Díaz-Lõpez A, Moreno-Bueno G, Castilla MÁ, Rosa-Rosa JM, Cano A, Palacios J. 2014. A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. J Pathol 232:319–329.
13. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. 2011. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem 286:25992–26002.
14. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong STC, Choi H, El Rayes T, Ryu S, Troeger J, Schwabe RF, Vahdat LT, Altorki NK, Mittal V, Gao D. 2015. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527:472–476.
15. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. 2008. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593–601.
16. Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR, Goel A. 2012. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 62:1315–1326.
17. Karihtala P, Auvinen P, Kauppila S, Haapasaari K-M, Jukkola-Vuorinen A, Soini Y. 2013. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: Association with an aggressive tumour phenotype. Breast Cancer Res Treat 138:81–90.
18. Knezevic J, Pfefferle A, Petrovic I, Greene S, Perou C, Rosen J. 2015. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. Oncogene 34:5997–6006.
19. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celia-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y. 2011. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 17:1101–1108.
20. Lehmann BDB, Bauer JAJ, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. 2011. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750–2767.
21. Lim Y-Y, Wright JA, Attema JL, Gregory PA, Bert AG, Smith E, Thomas D, Lopez AF, Drew PA, Khew-Goodall Y, Goodall GJ. 2013. Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. J Cell Sci 126:2256–2266.
22. Lombaerts M, van Wezel T, Philippo K, Dierssen JWF, Zimmerman RME, Oosting J, van Eijk R, Eilers PH, van de Water B, Cornelisse CJ, Cleton-Jansen A-M. 2006. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer 94:661–671.
23. Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Fuso Nerini I, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, Buda A, Romualdi C, D'Incalci M. 2011. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: A retrospective study of two independent tumour tissue collections. Lancet Oncol 12:273–285.
24. Meidhof S, Brabletz S, Lehmann W, Preca B-T, Mock K, Ruh M, Schuler J, Berthold M, Weber A, Burk U, Lubbert M, Puhr M, Culig Z, Wellner U, Keck T, Bronsert P, Kusters S, Hopt UT, Stemmler MP, Brabletz T. 2015. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO molecular Medicine 7:831–847.
25. Muggerud AA, Rønneberg JA, Wärnberg F, Botling J, Busato F, Jovanovic J, Solvang H, Bukholm I, Kristensen VN, Sørlie T, Tost J. 2010. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Research 12:R3.
26. Neves R, Scheel C, Weinhold S, Honisch E, Iwaniuk KM, Trompeter H-I, Niederacher D, Wernet P, Santourlidis S, Uhrberg M. 2010. Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res Notes 3:219.
27. Okugawa Y, Toiyama Y, Tanaka K, Matsusita K, Fujikawa H, Saigusa S, Ohi M, Inoue Y, Mohri Y, Uchida K, Kusunoki M. 2012. Clinical significance of Zinc finger E-box Binding homeobox 1 (ZEB1) in human gastric cancer. J Surg Oncol 106:280–285.
28. Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ. 2013. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia 15:180–191.
29. Pichler M, Ress AL, Winter E, Stiegelbauer V, Karbiener M, Schwarzenbacher D, Scheideler M, Ivan C, Jahn SW, Kiesslich T, Gerger A, Bauernhofer T, Calin GA, Hoefler G. 2014. MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. Br J Cancer 110:1614–1621.
30. Puisieux A, Brabletz T, Caramel J. 2014. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 16:488–494.
31. Rodríguez-Paredes M, Esteller M. 2011. Cancer epigenetics reaches mainstream oncology. Cancer Epigenetics 17:330–339.
32. Santarosa M, Del Col L, Tonin E, Caragnano A, Viel A, Maestro R. 2009. Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: Implication for tailored treatments of BRCA1 mutation carriers. Mol Cancer Ther 8:844–854.
33. Schmalhofer O, Brabletz S, Brabletz T. 2009. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28:151–166.
34. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RAR, Lao K, Clarke MF. 2009. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138:592–603.
35. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A, Hlubek F, Jung A, Strand D, Eger A, Kirchner T, Behrens J, Brabletz T. 2008. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 68:537–544.
36. Sun L, Kokura K, Izumi V, Koomen JM, Seto E, Chen J. 2015. MPP 8 and SIRT 1 crosstalk in E-cadherin gene silencing and epithelial – mesenchymal transition. EMBO Rep 16:689–699.
37. Tam WL, Weinberg RA. 2013. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19:1438–1449.
38. Tang H, Deng M, Tang Y, Xie XX, Guo J, Kong Y, Ye F, Su Q, Xie XX. 2013. miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression. Clin Cancer Res 19:5602–5612.
39. Tryndyak VP, Beland FA, Pogribny IP. 2010. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 126:2575–2583.
40. Tuna M, Machado AS, Calin GA. 2016. Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases. Genes, Chromosome Cancer 55:193–214.
41. Tuomarila M, Luostari K, Soini Y, Kataja V, Kosma V-M, Mannermaa A. 2014. Overexpression of microRNA-200c predicts poor outcome in patients with PR-negative breast cancer. PloS One 9:e109508.
42. Vrba L, Garbe JC, Stampfer MR, Futscher BW. 2011. Epigenetic regulation of normal human mammary cell type-specific miRNAs. Genome Res 21:2026–2037.
43. Wang J, Scully K, Zhu X, Cai L, Zhang J, Prefontaine GG, Krones A, Ohgi KA, Zhu P, Garcia-Bassets I, Liu F, Taylor H, Lozach J, Jayes FL, Korach KS, Glass CK, Fu X-D, Rosenfeld MG. 2007. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 446:882–887.
44. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T. 2009. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11:1487–1495.
45. Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS, Borre M, Peter ME, Ørntoft TF, Kjems J, Clark SJ. 2011. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 128:1327–1334.
46. Yu S-J, Hu J-Y, Kuang X-Y, Luo J-M, Hou Y-F, Di G-H, Wu J, Shen Z-Z, Song H-Y, Shao Z-M. 2013. MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin Cancer Res 19:1389–1399.
47. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu C-C, LeBleu VS, Kalluri R. 2015. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527:525–530.